ClinicalTrials.gg
RecruitingNCT06313866Updated Feb 20, 2025

the Clinical Effect of TCM Sniffing Therapy Combined With Electroacupuncture in PSCI

An interventional study of control and Electronuchal acupuncture group treatment in Stroke, sponsored by Hangzhou Medical College. Recruiting at 1 site in China. Open to participants aged Up to 70 Years. Per ClinicalTrials.gov, last updated 2025-02-20.

Sponsored by Hangzhou Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
Up to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 613 studies in Stroke with a site in China — 242 open to participants now, 263 under way, 21 of them phase 3. Stroke · China.

Planned enrollment
186th of 432
220 · median 169
Started
2024
with 70 others
No phase
264 of 613
123 open now
Primary completion
2025-04
later than 45 of 262 live
Registered
402nd of 613
by date

Among the 613 studies in Stroke with a site in China, this one is the 186th largest by planned enrollment of the 432 interventional ones that give a count, is one of 71 that started in 2024, is one of 264 with no phase, reaches primary completion later than 45 of the 262 other live ones, and was the 402nd registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

242 of the 613 studies in Stroke with a site in China are open now. Recruiting first, the newest first:

237 more — sign in →

All 242 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: Up to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 613 studies in Stroke with a site in China, or all of them as a file.
02

Study summary

The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, electroacupuncture combined with olfactory therapy group, and sham group with 35 people in each group. After the end of the treatment, the clinical efficacy was evaluated.

Read the detailed description

The patients with cognitive impairment after stroke were divided into control group, electroacupuncture group, olfactory therapy group, and electroacupuncture combined with olfactory therapy group, and sham group with 35 people in each group. All patients were treated with conventional drugs and general supportive treatment, and on the basis of this, the electroacupuncture group was given electroacupuncture treatment at bilateral Fengchi and Gongxue, the smell suction therapy group was given the intervention of volatile oil nasal suction of Acorus calamus, and the electroacupuncture group combined with smell and suction therapy group was given electroacupuncture treatment at the same time as the electroacupuncture treatment of bilateral Fengchi and Gongxue. In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture. After the 1 month innervation,the main efficacy indicators: Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Barthel Index (MBI) score, and the secondary efficacy indicators: Transcranial Doppler (TCD), near-infrared functional brain imaging , magnetic resonance examination, the heart rate,blood pressure and the State Trait Anxiety Inventory (STAI)are collected.

03

Conditions studied

  • Stroke

Browse trials for

04

Who can participate

Ages eligible
Up to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1) Stroke as per the TCM definition, presenting symptoms include unilateral paresis or paralysis, sensory deficits, speech impairment, and hemianopsia. PSCI diagnosis involves deficits in at least one cognitive domain and severe disruption of instrumental ADLs/ADLs.; (2) The scores on the scale must adhere to the following criteria: Less than 17 points for individuals with illiteracy, less than 20 points for those with primary school education, and less than 24 points for individuals with a middle school education or higher.; (3) Aged under 70 years; (4) No history of mental illness, clear consciousness, stable vital signs, and able to complete the scale assessment; (5) Within 6 months post-stroke, diagnosed as a patient in the recovery period of cerebral infarction (or cerebral hemorrhage) at admission; (6) Signed by the patient or their family.

Exclusion criteria

Exclusion Criteria:

  • (1) ; (2) Subarachnoid hemorrhage; (3) History of severe liver or kidney diseases, mental illness, epilepsy, asthma, or obstructive pulmonary diseases; (4) Occurrence of cognitive impairment prior to stroke; (5) Severe communication barriers; (6) Substance abuse or heavy alcohol consumption; (7) Implanted cardiac pacemakers or other electronic devices.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • No intervention
    control

    Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

  • Experimental
    Electronuchal acupuncture group treatment

    Use the neck needle to take the Fengchi and Gongxue on both sides (1.5cm directly below Fengchi point).

    Dietary Supplement: control · Other: Electronuchal acupuncture group treatment

  • Experimental
    Smell therapy group treatment

    The volatile oil of Acorus calamus is packed in the sniffer. Smell at the sniffing end, breathe evenly, 5-10 minutes each time, 3-5 times a day, for a total of 4 weeks of treatment.

    Dietary Supplement: control · Other: Smell therapy group treatment

  • Experimental
    The combined treatment

    The electro-neuchal acupuncture combined with sniffing and suction therapy group is treated with sniffing and suction therapy on the basis of electro-neuchal acupuncture treatment.

    Dietary Supplement: control · Other: Electronuchal acupuncture combined with smell and inhalation therapy group treatment

  • Other
    normal

    The volatile oil of Acorus calamus is packed in the sniffer. Smell at the sniffing end, breathe evenly, 5-10 minutes each time, 3-5 times a day, for a total of 4 weeks of treatment.

    Other: Smell therapy group treatment

  • Sham comparator
    Sham group

    In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.

    Other: Sham stimulation

Interventions

  • Dietary supplementcontrol

    Donepezil hydrochloride was administered at 5 mg once a day (nightly) for 30 days without adverse reactions and then increased to 10 mg once a day (nightly) for 4 weeks.

  • OtherElectronuchal acupuncture group treatment

    Electronuchal acupuncture

  • OtherSmell therapy group treatment

    nasal suction intervention with volatile oil of Acorus calamus

  • OtherElectronuchal acupuncture combined with smell and inhalation therapy group treatment

    On the basis of electric nuchal acupuncture treatment, sniffing and inhalation therapy is given.

  • OtherSham stimulation

    In the sham stimulation group, non-transdermal comfortable acupuncture will be used to make the patients experience a feeling similar to acupuncture.

06

What researchers measure

Primary outcomes

  1. MoCA

    Montreal Cognitive Assessment Scale

    Time frame: 0,4 weeks after the intervention, 8 weeks after the intervention

Secondary outcomes

  1. MMSE

    Mini-Mental State Examination

    Time frame: 0,4 weeks after the intervention,8 weeks after the intervention

  2. MBI

    Barthel index score

    Time frame: 0,4 weeks after the intervention,8 weeks after the intervention

  3. TCD

    Transcranial Doppler examination

    Time frame: 0,4 weeks after the intervention

  4. Near-infrared functional imaging of the brain

    Near-infrared functional imaging of the brain

    Time frame: 0,4 weeks after the intervention

  5. Magnetic resonance scanning

    Magnetic resonance scanning

    Time frame: 0,4 weeks after the intervention

  6. the State Trait Anxiety Inventory (STAI)

    the State Trait Anxiety Inventory (STAI)

    Time frame: 0,4 weeks after the intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Apr 2025, 12 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 12 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2024
First posted
Mar 15, 2024
StartActual
Apr 1, 2024
Primary completionEst.
Apr 1, 2025
CompletionEst.
Jun 1, 2025
Last update
Feb 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06313866
Lead sponsor
Hangzhou Medical College
Responsible party
Sponsor
First posted
Mar 15, 2024
Start date
Apr 1, 2024
Primary completion
Apr 1, 2025 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Feb 20, 2025

Study contacts

Xinyun Dr LI, Doctor
Contact
lxyjasmine2010@163.com
8618069783240
Xinyun Li, doctor
principal investigator · hangzhou medical colleage

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion